trial

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

NCTId NCT06572449
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 173 (actual)
Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Primary completion 2025-03-13
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
173 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2024-10-28
Primary completion
2025-03-13
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Karuna Therapeutics, Inc., a Bristol Myers Squibb companyLead Sponsor

Sites

6 total
Los Alamitos, United StatesRiverside, United StatesHollywood, United StatesAtlanta, United StatesDecatur, United StatesMarlton, United States

Linked catalysts

1
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effe — primary completion2025-03-13

Facts & assertions

4 sourced
Enrollment
173
Phase
PHASE3
Primary Completion Date
2025-03-13
Status
COMPLETED
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
company
indication
Schizophrenia
indication
Schizophrenia
indication
Mental Disorders
indication